Aravive, Inc. to Delist from The Nasdaq Stock Market
HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq:ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market (“Nasdaq”) and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and suspend its public reporting obligations.
Related news for (ARAV)
- Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
- Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
- Aravive To Participate in Piper’s 34th Annual Healthcare Conference
- Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates